The Relationship Between Serum Very Long-chain Saturated Fatty Acids and Chronic Kidney Disease
Abstract
Objective
To investigate the relationship between very long chain saturated fatty acids (VLCSFAs) levels in the serum of American adults and chronic kidney disease (CKD), thereby providing new insights for the prevention and treatment of CKD.
Methods
Using data from the 2011–2014 National Health and Nutrition Examination Survey (NHANES), individuals under 20 years of age and those lacking serum creatinine, blood urea nitrogen, urine albumin-to-creatinine ratio (uACR), or other covariate data were excluded. Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI (2009) equation. The independent relationship between VLCSFAs and CKD was examined using weighted multivariate logistic regression, the XGBoost machine learning model, and subgroup analyses. Restricted cubic splines (RCS) were used to test for nonlinear associations.
Results
A total of 4164 participants were analyzed. Serum VLCSFAs levels differed significantly between the CKD and non-CKD groups (P < 0.05). In fully adjusted models, weighted multivariate logistic regression revealed a decreasing trend in CKD risk with increasing serum VLCSFAs levels, particularly for docosanoic acid, tricosanoic acid, and lignoceric acid, which significantly reduced CKD risk (docosanoic acid: odds ratio [OR] = 0.17, 95% CI: 0.06-0.43, P < 0.001; tricosanoic acid: OR = 0.02, 95% CI: 0.002-0.15, P < 0.001; lignoceric acid: OR = 0.13, 95% CI: 0.04-0.40, P < 0.001). RCS analysis showed no nonlinear association between VLCSFAs and CKD. The XGBoost machine learning model identified triacontanoic acid as the most important factor for CKD risk. Subgroup analysis indicated that docosanoic acid, tricosanoic acid, and lignoceric acid exerted protective effects only in CKD participants with concomitant hypertension, while showing no impact on those with diabetes, coronary heart disease, or stroke.
Conclusion
Elevated circulating VLCSFAs levels in US adults are associated with reduced CKD risk. Further large-scale prospective studies are needed to validate these findings.
Keywords: Very long-chain saturated fatty acids, Chronic kidney disease, Extreme gradient boosting, Cross-sectional study
Full Text:
PDFReferences
ROMAGNANI P, AGARWAL R, CHAN J C N, et al. Chronic kidney disease. Nat Rev Dis Primers, 2025, 11(1): 8. doi: 10.1038/s41572-024-00589-9.
Global Nutrition Target Collaborators. Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet, 2025, 404(10471): 2543-2583. doi: 10.1016/S0140-6736(24)01821-X.
GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet, 2024, 403(10440): 2204-2256. doi: 10.1016/S0140-6736(24)00685-8.
LEMAITRE R N, KING I B, KABAGAMBE E K, et al. Genetic loci associated with circulating levels of very long-chain saturated fatty acids. J Lipid Res, 2015, 56(1): 176-184. doi: 10.1194/jlr.M052456.
GARG M L, BLAKE R J, WILLS R B. Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. J Nutr, 2003, 133(4): 1060-1063. doi: 10.1093/jn/133.4.1060.
LAM C, WONG D, CEDERBAUM S, et al. Peanut consumption increases levels of plasma very long chain fatty acids in humans. Mol Genet Metab, 2012, 107(3): 620-622. doi: 10.1016/j.ymgme.2012.07.015.
LEMAITRE R N, KING I B. Very long-chain saturated fatty acids and diabetes and cardiovascular disease. Curr Opin Lipidol, 2022, 33(1): 76-82. doi: 10.1097/MOL.0000000000000806.
TANNO H, SASSA T, SAWAI M, et al. Production of branched-chain very-long-chain fatty acids by fatty acid elongases and their tissue distribution in mammals. Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(1): 158842. doi: 10.1016/j.bbalip.2020.158842.
BOCKUS L B, BIGGS M L, LAI H T M, et al. Assessment of plasma phospholipid very-long-chain saturated fatty acid levels and healthy aging. JAMA Netw Open, 2021, 4(8): e2120616. doi: 10.1001/jamanetworkopen.2021.20616.
FRETTS A M, IMAMURA F, MARKLUND M, et al. Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies. Am J Clin Nutr, 2019, 109(4): 1216-1223. doi: 10.1093/ajcn/nqz005.
LEMAITRE R N, MCKNIGHT B, SOTOODEHNIA N, et al. Circulating very long-chain saturated fatty acids and heart failure: the cardiovascular health study. J Am Heart Assoc, 2018, 7(21): e010019. doi: 10.1161/JAHA. 118.010019.
TAO X, LIU L, MA P, et al. Association of circulating very long-chain saturated fatty acids with cardiovascular mortality in NHANES 2003-2004, 2011-2012. J Clin Endocrinol Metab, 2024, 109(2): e633-e645. doi: 10.1210/clinem/dgad561.
NOELS H, LEHRKE M, VANHOLDER R, et al. Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol, 2021, 17(8): 528-542. doi: 10.1038/s41581-021-00423-5.
MAZIDI M, KENGNE A P, SIERVO M, et al. Association of dietary intakes and genetically determined serum concentrations of mono and poly unsaturated fatty acids on chronic kidney disease: insights from dietary analysis and mendelian randomization. Nutrients, 2022, 14(6): 1231. doi: 10.3390/nu14061231.
LIU Z X, HONG Q, PENG D H, et al. Evaluation of serum free fatty acids in chronic renal failure: evidence from a rare case with undetectable serum free fatty acids and population data. Lipids Health Dis, 2019, 18(1): 151. doi: 10.1186/s12944-019-1093-5.
MITROFANOVA A, MERSCHER S, FORNONI A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat Rev Nephrol, 2023, 19(10): 629-645. doi: 10.1038/s41581-023-00741-w.
[17] BENAIM C, FREITAS-VILELA A A, PINTO T J P, et al. Early pregnancy body mass index modifies the association of pre-pregnancy dietary patterns with serum polyunsaturated fatty acid concentrations throughout pregnancy in Brazilian women. Matern Child Nutr, 2018, 14(1): e12480. doi: 10.1111/mcn.12480.
LEVEY A S, STEVENS L A, SCHMID C H, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009, 150(9): 604-612. doi: 10.7326/0003-4819-150-9-200905050-00006.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002, 39(2 Suppl 1): S1-266.
TANG X, SHI Y Y, WANG J Q, et al. Expert recommendations on the early screening path of adult chronic kidney disease and its complications in China (2023 edition). Chinese Journal of Practical Internal Medicine, 2023, 43(3): 198-205. doi: 10.19538/j.nk2023030105.
WEBSTER A C, NAGLER E V, MORTON R L, et al. Chronic kidney disease. Lancet, 2017, 389(10075): 1238-1252. doi: 10.1016/S0140-6736 (16)32064-5.
Chinese Preventive Medicine Association for Kidney Disease. Guidelines for the early evaluation and management of chronic kidney disease in China. Chin J Intern Med, 2023, 62(8): 902-930. doi: 10.3760/cma.j. cn112138-20221013-00755.
LAI K Z H, SEMNANI-AZAD Z, BOUCHER B A, et al. Association of serum very-long-chain saturated fatty acids with changes in insulin sensitivity and beta-cell function: the Prospective Metabolism and Islet Cell Evaluation (PROMISE) cohort. Diabetes, 2023, 72(11): 1664-1670. doi: 10.2337/db22-1050.
WU S, LUO H, ZHONG J, et al. Differential associations of erythrocyte membrane saturated fatty acids with glycemic and lipid metabolic markers in a Chinese population: a cross-sectional study. Nutrients, 2024, 16(10): 1507. doi: 10.3390/nu16101507.
LIU M, ZUO L S, SUN T Y, et al. Circulating very-long-chain saturated fatty acids were inversely associated with cardiovascular health: a prospective cohort study and meta-analysis. Nutrients, 2020, 12(9): 2709. doi: 10.3390/nu12092709.
Refbacks
- There are currently no refbacks.
